Key clinical point: Icosapent ethyl reduced risk of cardiovascular events at a lower cost.
Major finding: Mean cost during the trial period of icosapent ethyl was $27,567 versus $28,205 for placebo.
Data source: REDUCE-IT trial of 8,179 patients randomized to icosapent ethyl or placebo.
Disclosures: Dr. Weintraub disclosed financial relationships with Amarin Pharma and AstraZeneca.
Weintraub WS et al. AHA 2019, Session FS.AOS.F1.